Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Rises 71.9%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 8,346,026 shares, an increase of 71.9% from the September 15th total of 4,853,831 shares. Based on an average daily trading volume, of 2,551,015 shares, the short-interest ratio is currently 3.3 days. Approximately 5.9% of the company’s stock are sold short.

Inventiva Trading Up 7.8%

Shares of NASDAQ:IVA traded up $0.23 during trading on Thursday, reaching $3.10. 1,821,915 shares of the stock traded hands, compared to its average volume of 932,876. The stock has a 50-day moving average of $4.11 and a two-hundred day moving average of $4.50. Inventiva has a 52-week low of $2.82 and a 52-week high of $7.98.

Inventiva (NASDAQ:IVA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. On average, equities research analysts forecast that Inventiva will post -0.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Platt Investment Counsel LLC purchased a new position in Inventiva in the 3rd quarter worth about $45,000. Engineers Gate Manager LP lifted its stake in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP bought a new position in Inventiva during the 1st quarter valued at about $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Inventiva during the 4th quarter valued at about $603,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IVA. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company. Truist Financial lifted their price target on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Weiss Ratings lowered shares of Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. Finally, Piper Sandler restated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Inventiva has an average rating of “Buy” and a consensus target price of $15.86.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.